phenylalanine has been researched along with Thrombosis in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (14.29) | 18.7374 |
| 1990's | 3 (21.43) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bereczky, Z; Boda, Z; Gindele, R; Ilonczai, P; Kovács, B; Marján, E; Muszbek, L; Oláh, Z; Pfliegler, G; Selmeczi, A; Speker, M; Udvari, Á | 1 |
| Gui, L; Peng, S; Wang, Y; Wu, J; Zhang, X; Zhao, M; Zhao, S; Zhu, H | 1 |
| Ziakas, PD | 1 |
| Jiang, X; Liu, J; Peng, S; Wang, W; Wang, Y; Wu, G; Wu, J; Yang, Y; Zhao, M; Zheng, M | 1 |
| Iványi, JL; Marton, E; Plander, M | 1 |
| Collen, A; Grimbergen, J; Hanemaaijer, R; Koolwijk, P; Lupu, F; Peters, E; Quax, PH; van Hinsbergh, VW; van Lent, N | 1 |
| Giddings, JC; Hashimoto, M; Matsuo, O; Oiwa, K; Okada, K; Okada, Y; Okamoto, S; Ueshima, S; Yamamoto, J | 1 |
| CHAMBERS, DA; SALZMAN, EW | 1 |
| Ikarugi, H; Inoue, A; Ishii, H; Okada, Y; Tsuda, Y; Yamamoto, J; Yamashita, T | 1 |
| Fujimoto, H; Gotoh, A; Ito, Y; Kiguchi, T; Kimura, Y; Miyazawa, K; Ohyashiki, JH; Ohyashiki, K; Tauchi, T | 1 |
| Evans, H; Feldman, PA; McGrath, S | 1 |
| Ichinose, A; Mlyata, T; Saito, T; Sakata, T; Tsutsumi, S | 1 |
| Appleby, SD; Baskin, EP; Chen, IW; Dancheck, KB; Gardell, SJ; Lewis, SD; Lucas, BJ; Lumma, WC; Lyle, EA; Lynch, JJ; Tucker, TJ; Vacca, JP; Woltmann, R | 1 |
| Jones, R; Kim, DN; Lee, KT; Thomas, WA | 1 |
14 other study(ies) available for phenylalanine and Thrombosis
| Article | Year |
|---|---|
Founder effect is responsible for the p.Leu131Phe heparin-binding-site antithrombin mutation common in Hungary: phenotype analysis in a large cohort.
Topics: Adolescent; Adult; Aged; Antithrombins; Arteries; Binding Sites; Child; Child, Preschool; Cohort Studies; Factor Xa; Female; Founder Effect; Genetic Association Studies; Heparin; Heterozygote; Humans; Hungary; Leucine; Microsatellite Repeats; Middle Aged; Mutation; Phenotype; Phenylalanine; Polymorphism, Single Nucleotide; Pregnancy; Pregnancy Complications, Cardiovascular; Sensitivity and Specificity; Thrombosis; Young Adult | 2016 |
Topics: Animals; Antineoplastic Agents; Carbolines; Cell Line, Tumor; Cell Proliferation; DNA; DNA Cleavage; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Inflammation; Male; Mice; Mice, Inbred ICR; Molecular Docking Simulation; Molecular Structure; Nanoparticles; Neoplasms, Experimental; Phenylalanine; Structure-Activity Relationship; Thrombosis | 2017 |
Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain.
Topics: Humans; Janus Kinase 2; Phenylalanine; Risk Factors; Thrombocythemia, Essential; Thrombocytosis; Thrombosis; Uncertainty; Valine | 2008 |
Pyrolo[1,2:4,5]-1,4-dioxopyrazino[1,2:1,6]pyrido[3,4-b]indoles: a group of urokinase inhibitors, their synthesis, and stereochemistry-dependent activity.
Topics: Animals; Antifibrinolytic Agents; Blood Proteins; Disease Models, Animal; Enzyme Activation; Heterocyclic Compounds, 4 or More Rings; Indoles; Male; Mice; Mice, Inbred ICR; Phenylalanine; Rats; Rats, Wistar; Stereoisomerism; Thrombosis; Urokinase-Type Plasminogen Activator | 2011 |
[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Topics: Adult; Aged; Bone Marrow Neoplasms; Chronic Disease; Female; Humans; Janus Kinase 2; Male; Middle Aged; Mutation; Myeloproliferative Disorders; Phenylalanine; Polycythemia Vera; Polymerase Chain Reaction; Predictive Value of Tests; Primary Myelofibrosis; Retrospective Studies; Signal Transduction; Thrombocythemia, Essential; Thrombosis; Valine | 2011 |
Membrane-type matrix metalloproteinase-mediated angiogenesis in a fibrin-collagen matrix.
Topics: Adenoviridae; Aprotinin; Cells, Cultured; Collagen; Culture Media; Defective Viruses; Drug Synergism; Endothelial Growth Factors; Endothelium, Vascular; Fibrin; Fibroblast Growth Factor 2; Genetic Vectors; Heart Diseases; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Matrix Metalloproteinase 1; Matrix Metalloproteinase 2; Matrix Metalloproteinases, Membrane-Associated; Metalloendopeptidases; Neovascularization, Pathologic; Neovascularization, Physiologic; Phenylalanine; Protease Inhibitors; Thiophenes; Thrombosis; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-3; Transduction, Genetic; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Suppression of argatroban-induced endogenous thrombolysis by PKSI-527, and antibodies to TPA and UPA, evaluated in a rat arterial thrombolysis model.
Topics: Animals; Antibodies; Arginine; Drug Antagonism; Fibrinolysin; Fibrinolysis; Fibrinolytic Agents; Kallikreins; Male; Mesenteric Arteries; Phenylalanine; Pipecolic Acids; Plasma Kallikrein; Rats; Rats, Wistar; Sulfonamides; Thrombolytic Therapy; Thrombosis; Tissue Plasminogen Activator; Tranexamic Acid; Urokinase-Type Plasminogen Activator | 2003 |
INHIBITION OF ADP-INDUCED PLATELET AGGREGATION BY SUBSTITUTED AMINO-ACIDS.
Topics: Adenine Nucleotides; Adenosine Diphosphate; Alanine; Alkylation; Amino Acids; Aminocaproates; Aminocaproic Acid; Arginine; Blood Platelets; Butyrates; Glutamine; Glycine; Guanidines; Leucine; Pharmacology; Phenylalanine; Platelet Aggregation; Proline; Research; Thrombosis; Tyrosine | 1964 |
Synergistic antithrombotic effect of a combination of NO donor and plasma kallikrein inhibitor.
Topics: Adult; Aged; Blood Platelets; Drug Synergism; Female; Fibrinolytic Agents; Humans; In Vitro Techniques; Kallikreins; Male; Middle Aged; Nitric Oxide Donors; Phenylalanine; S-Nitrosoglutathione; Thrombosis; Tranexamic Acid | 2005 |
Leukocytosis is linked to thrombosis at diagnosis, while JAK2 V617F mutation is associated with thrombosis during the course of essential thrombocythemia.
Topics: Aged; Female; Humans; Janus Kinase 2; Leukocytosis; Male; Middle Aged; Mutation; Phenylalanine; Thrombocythemia, Essential; Thrombosis; Valine | 2008 |
Sensitivity of the fibrinogen clotting time: an in vitro test of potential thrombogenicity.
Topics: Antithrombin III; Benzamidines; Blood Coagulation; Blood Coagulation Factors; Blood Coagulation Tests; Fibrinogen; Heparin; Hirudins; Humans; Phenylalanine; Piperidines; Reproducibility of Results; Temperature; Thrombin; Thrombosis | 1994 |
Genetic diagnosis of dysplasminogenemia: detection of an Ala601-Thr mutation in 118 out of 125 families and identification of a new Asp676-Asn mutation.
Topics: Adult; Alanine; Asparagine; Aspartic Acid; Female; Genetic Testing; Humans; Male; Mutation; Phenylalanine; Plasminogen; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single-Stranded Conformational; Sequence Analysis, DNA; Structure-Activity Relationship; Threonine; Thrombosis | 1996 |
Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy.
Topics: Animals; Biological Availability; Dipeptides; Dogs; Fibrinolytic Agents; Lipid Metabolism; Male; Molecular Structure; Partial Thromboplastin Time; Phenylalanine; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Thrombin; Thrombosis | 1997 |
Studies of fibrinogen synthesis in rats fed thrombogenic diets.
Topics: Animals; Arachis; Blood Proteins; Butter; Carbon Isotopes; Cholesterol; Diet; Dietary Proteins; Fibrinogen; Glycine; In Vitro Techniques; Leucine; Liver; Microscopy, Electron; Microsomes; Nucleic Acids; Phenylalanine; Propylthiouracil; Protein Biosynthesis; Rats; Thrombosis; Toxicology | 1966 |